EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?
- PMID: 31508163
- PMCID: PMC6717615
- DOI: 10.1183/20734735.0363-2018
EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?
Abstract
In the EOLIA trial, early use of ECMO did not significantly improve mortality at 60 days in patients with severe ARDS, but when used as a rescue modality ECMO might help improve survival http://bit.ly/2XOjwSE.
Conflict of interest statement
Conflict of interest: M. Sameed has nothing to disclose. Conflict of interest: Z. Meng has nothing to disclose. Conflict of interest: E.T. Marciniak has nothing to disclose.
References
-
- Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA 2018; 319: 698–613. - PubMed
-
- Zapol WM, Snider MT, Hill JD, et al. . Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 1979; 242: 2193–2196. - PubMed
-
- Morris AH, Wallace CJ, Menlove RL, et al. . Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 149: 295–305. - PubMed
-
- Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, et al. . Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009; 302: 1888–1895. - PubMed
LinkOut - more resources
Full Text Sources